Applied therapeutics announces positive topline results of pivotal phase 2 action-galactosemia study of at-007 in galactosemia patients

Applied therapeutics announces positive topline results of pivotal phase 2 action-galactosemia study of at-007 in galactosemia patients.applied therapeutics - at-007 demonstrated a robust and sustained reduction in galactitol versus placebo.applied therapeutics - at-007 was well-tolerated; no drug-related adverse events reported at any dose to date.applied therapeutics - expects to file for regulatory approval of at-007 in second half of 2020.
APLT Ratings Summary
APLT Quant Ranking